Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 35-41

  Dulac, Olivier ^a   Alvarez, Jean Claude ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Biochimie Pharmacologie   (France)

Author keywords

Bioequivalence; Chronosphere; Modified release granules; Pharmacokinetics; Sustained release formulations; Valproate

Indexed keywords

DEPAKINE CHRONO; DEPAKINE CHRONOSPHERE; VALPROATE SEMISODIUM; VALPROIC ACID; YOGHURT;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TABLET;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EATING; GASTROINTESTINAL TRACT; HALF-LIFE; HEADACHE; HUMANS; MALE; TECHNOLOGY, PHARMACEUTICAL; THERAPEUTIC EQUIVALENCY; VALPROIC ACID;

EID: 11144239781     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.35.55626     Document Type: Article

References (15)

1. Perucca E. Valproate: a summary of the pharmacological and therapeutic properties of a mainstay antiepileptic drug after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
2. Löscher W. Valproate: a review of its basic pharmacology after 35 years of clinical use in the pharmacotherapy of epilepsy. CNS Drugs 2002;16:669-94.
3. Davis R, David HP, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
4. Bauer LA, Davis R, Wilensky A, Raisys VA, Levy RH. Diurnal variation in valproic acid clearance. Clin Pharmacol Ther 1984;37:697-700.
5. Yoshiyama Y, Nakano S, Ogawa N. Chronopharmacokinetic study of valproic acid in man: comparison of oral and rectal administration. J Clin Pharmacol 1989;29:1048-52.
6. Roberts D, Easter D, O'Bryan-Tear G. Epilim Chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Dispos 1996;17:175-82.
7. Bergmann A, Schmidt D, Hutt HJ, Elger CE. Epilepsy treatment with a sustained-release formulation of valproate: experience with 1172 patients. Akt Neurologie 1999;26:1-5.
8. Quinn HM, Takarewski JJ, inventors. Turbulent-flow chromatography. Int patent WO 97 16 16724. 1997.
9. Franke G, Diletti E, Hoffmann C, Zschiesche M, Scheuch E, Siegmund W. Relative bioavailability of different valproic acid formulations. Int J Clin Pharmacol Ther 1995;33:653-7.
10. Barre J, Berger Y. Pharmacokinetics of a newly developed sustained release formulation of sodium valproate. In: Chadwick D, ed. Proceedings of the fourth international symposium on sodium valproate and epilepsy. London: Royal Society of Medicine Services, 1989:178-84.
11. Chun AH, Hoffman DJ, Friedman N, Carrigan PJ. Bioavailability of valproic acid under fasting/non-fasting regimens. J Clin Pharmacol 1980;20:30-6.
12. Levy RH, Cenravid B, Loiseau P, et al. Meal dependent absorption of enteric coated valproate. Epilepsia 1980; 21:273-80.
13. Theison M, Heimann G, Hahn H, Herma I. Bioavailability of three sodium valproate preparations under fasting and non-fasting regimen. Br J Clin Pract Symp 1982;18:204-8.
14. Royer-Morrot MJ, Zhiri A, Jacob F, Necciari J, Lascombes F, Royer RJ. Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. Biopharm Drug Dispos 1993;14:511-18.
15. Retzow A, Venscapell B, Wangemann M. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. Arzneimittelforschung 1997;47:1347-50.